A Multinational Double-Blind, Randomised Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer.

Trial Profile

A Multinational Double-Blind, Randomised Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs Sorafenib (Primary) ; Docetaxel; Letrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms SOR; TIES
  • Most Recent Events

    • 27 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 13 Sep 2011 Results will be presented as a late-breaking abstract at ECCO-ESMO 2011, according to a Bayer press release.
    • 07 Apr 2010 Planned initiation date (22 Nov 2007) added as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top